• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

UK - Gov: COVID-19 variant Delta trend & Omicron becoming dominant, and now Omicron 2.....

https://coronavirus.data.gov.uk/
https://www.bbc.co.uk/news/uk-51768274

_122490060_uk_card_with_vax_booster_23dec-nc.png


Dr. Clarke, interviewed on BBC also states that infection by Omicron is unlikely to provide protection to the Delta variant.
 
https://www.theguardian.com/world/2021/dec/24/omicron-covid-symptoms-uk-guidance-zoe-study

Omicron’s cold-like symptoms mean UK guidance ‘needs urgent update’


Lead scientist on Zoe Covid study calls official advice ‘misinformation’ in light of data about new variant
..
The most widespread symptoms of the Omicron variant now match those of common colds, with calls for the government to update its public health messaging to include a wider number of likely Covid symptoms.

The most common symptoms reported among users of the Zoe Covid app have been a running nose, headaches, fatigue, sneezing and sore throats, according to the study’s most recent analysis of confirmed cases in London.



Half of those reporting cold-like symptoms also tested positive for Covid, with no clear difference in the symptoms reported for Delta or Omicron infections. But only about half of infected users also reported the “classic three symptoms of fever, cough, or loss of sense of smell or taste”, according to the Zoe analysis.
 
COVID-19 vaccine surveillance report

Week 12
24 March 2022

UK Health Security Agency

Executive summary
Four coronavirus (COVID-19) vaccines have now been approved for use in the UK. Rigorous clinical trials have been undertaken to understand the immune response, safety profile and efficacy of these vaccines as part of the regulatory process. Ongoing monitoring of the vaccines as they are rolled out in the population is important to continually ensure that clinical and public health guidance on the vaccination programme is built upon the best available evidence.

UK Health Security Agency (UKHSA), formerly Public Health England (PHE), works closely with the Medicines and Healthcare Regulatory Agency (MHRA), NHS England, and other government, devolved administration and academic partners to monitor the COVID-19 vaccination programme. Details of the vaccine surveillance strategy are set on the pageCOVID-19: vaccine surveillance strategy (1). As with all vaccines, the safety of COVID-19vaccines is continuously being monitored by the MHRA. They conclude that overall, the benefits of COVID-19 vaccines outweigh any potential risks (2).

Vaccine effectiveness
Several studies of vaccine effectiveness have been conducted in the UK against different COVID-19 variants. Vaccine effectiveness against symptomatic disease with the Omicron variant is substantially lower than against the Delta variant, with rapid waning. However, protection against hospitalisation remains high, particularly after 3 doses.

Population impact
The impact of the vaccination programme on the population is assessed by taking into account vaccine coverage, evidence on vaccine effectiveness and the latest COVID-19 disease surveillance indicators.

Vaccine coverage tells us about the proportion of the population that have received one, 2 and 3 doses of COVID-19 vaccines. By 20 March 2022, the overall vaccine uptake in England for dose 1 was 69.5% and for dose 2 was 65.2%. Overall vaccine uptake in England in people with at least 3 doses was 50.8%. In line with the programme rollout, coverage is highest in the oldest age groups.

We present data on COVID-19 cases, hospitalisations and deaths by vaccination status. This raw data should not be used to estimate vaccine effectiveness as the data does not take into account inherent biases present such as differences in risk, behaviour and testing in the vaccinated and unvaccinated populations. Vaccine effectiveness is measured in other ways as detailed in the Vaccine effectiveness section below. ...

https://assets.publishing.service.g...63023/Vaccine-surveillance-report-week-12.pdf
 
Back
Top